Login
Toggle sidebar

Lint: iodine-131-iobenguane

iodine-131-iobenguane
En Dash
error

"beta minus emission – cytotoxic effects"

Line 5:28 · Use a hyphen-minus ('-') instead of an en-dash ('–').
Acronyms
warning

"Azedra was FDA-approved in 2018 for the treatment of patients 12 years and older with unresectable metastatic phaeochromocytomas and paragangliomas. It is manufactured by Progenics Pharmaceuticals, Inc., a Lantheus company, in the Unites States. In August 2023, Lantheus disclosed in regulatory filings that they will ultimately stop production of Azedra, continuing into the first quarter of 2024 to provide doses to patients 6,7."

Line 21:15 · 'FDA' has no definition. Spell it out if it's unfamiliar to the audience.
Headings Valid
warning

Expected headings

  • H1 Terminology
  • H1 Usage
  • H1 Epidemiology
  • H2 Risk factors
  • H2 Associations
  • H1 Clinical presentation
  • H2 Complications
  • H1 Diagnosis
  • H2 Diagnostic criteria
  • H2 Diagnostic clues
  • H1 Pathology
  • H2 Aetiology
  • H2 Location
  • H2 Classification
  • H2 Macroscopic appearance
  • H2 Microscopic appearance
  • H2 Immunophenotype
  • H2 Markers
  • H2 Genetics
  • H1 Radiographic features
  • H2 Plain radiograph
  • H2 Mammography
  • H2 Antenatal ultrasound
  • H2 Transoesophageal echocardiography
  • H2 Ultrasound
  • H2 CT
  • H3 Dual-energy CT
  • H2 Angiography (DSA)
  • H2 MRI
  • H2 CT/MRI
  • H2 Nuclear medicine
  • H3 PET-CT
  • H3 PET-MRI
  • H1 Radiology report
  • H1 Treatment and prognosis
  • H2 Complications
  • H1 History and etymology
  • H1 Differential diagnosis
  • H2 Clinical differential diagnosis
  • H1 Practical points
  • H1 See also

"Characteristics"

Line 2:1 · "Characteristics" is not a recognised heading for this article type.

"Use"

Line 10:1 · "Use" is not a recognised heading for this article type.

"Potential side effects"

Line 13:1 · "Potential side effects" is not a recognised heading for this article type.
Commas
suggestion

"Iodine-131 iobenguane, trade name Azedra, sometimes referred to as I-131 MIBG, is a theranostic (i.e. both therapeutic and diagnostic) agent used for the treatment of unresectable phaeochromocytomas, paragangliomas, neuroendocrine tumours, and neuroblastomas. It is produced using the high-specificity Ultratrace synthesis method to yield a high proportion of MIBG bound to the radiopharmaceutical Iodine-131, enabling specific targeting of the noradrenaline transporter."

Line 1:42 · More than 5 commas in a single sentence might make it more difficult to read.
Links
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0